drugset / Trial / NCT03223220
Quelling of Excitotoxicity in Acute Stroke With Ketamine
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 20 mg | Intravenous |
| Background | Midazolam | Small molecule | 1 mg | Other |